Medscape Conference Coverage, based on selected sessions at the:

American Society of Clinical Oncology (ASCO) 44th Annual Meeting

May 30 - June 03, 2008; Chicago, Illinois

This activity is not sanctioned by, nor a part of, the American Society of Clinical Oncology.

Video Highlights

  • Video Highlights From the ASCO 44th Annual Meeting

    Research that will affect clinical practice includes a study showing that zoledronic acid reduces relapse in early breast cancer and KRAS mutations predict which patients will respond to cetuximab.
    Medscape Medical News, June 13, 2008

Conference News

  • GCC Prognostic in Colorectal Cancer

    A new study is encouraging experts to take another look at the potential of guanylyl cyclase C as a predictive marker.
    Medscape Medical News, June 23, 2008
  • Hormonal Therapy for Prostate Cancer

    A study of 20,000 patients has found that continuous androgen-deprivation therapy for at least 6 months is associated with bone fractures and diabetes.
    Medscape Medical News, June 19, 2008
  • New Agents and Treatment Failures in Melanoma

    A review of new melanoma research presented at the ASCO meeting highlighted positive findings with axitinib, OncoVEX, and ipilimumab, but also highlighted the failure of tremelimumab and vaccination with ganglioside GM2-KLH21.
    Medscape Medical News, June 19, 2008
  • Quality of Life Linked to Cancer Survival

    Patients reporting a good quality of life have statistically significant better overall survival, suggest 2 large meta-analyses.
    Medscape Medical News, June 19, 2008
  • Adjuvant Gemcitabine for Pancreatic Cancer

    Treatment with gemcitabine improved both overall and disease-free survival in patients with pancreatic cancer who had undergone surgical resection.
    Medscape Medical News, June 17, 2008
  • Gemcitabine Plus Radiation in Pancreatic Cancer

    Gemcitabine combined with radiotherapy was associated with a small improvement in survival among patients with unresectable pancreatic cancer over gemcitabine alone.
    Medscape Medical News, June 17, 2008
  • Sorafenib in Asian-Pacific Liver Cancer Patients

    A new trial shows that sorafenib, recently approved for liver cancer, is effective in Asian patients with poorer health status and more metastases.
    Medscape Medical News, June 16, 2008
  • Combo Therapy Response Rates in WG

    Combining bortezomib, dexamethasone, and rituximab in the treatment of Waldenstrom's macroglobulinemia dramatically improved the rate of complete responses.
    Medscape Medical News, June 13, 2008
  • Chemotherapy Toxicity Linked to Polypharmacy

    Drug interactions appear to influence patients' reactions to chemotherapy.
    Medscape Medical News, June 13, 2008
  • Transcriptional Changes May Predict Lung Cancer

    Researchers say the transcripts come from immune-response-related genes and might form the basis for future blood-based lung cancer testing.
    Medscape Medical News, June 13, 2008
  • Modafinil Helps Severe Cancer-Related Fatigue

    The eugeroic agent used to treat narcolepsy may have another use, researchers say, and appears beneficial for patients with severe fatigue.
    Medscape Medical News, June 12, 2008
  • Improved Survival with Azacitidine in MDS

    An improvement in survival in myelodysplastic syndrome is seen even in patients who do not have a complete response to azacitidine.
    Medscape Medical News, June 12, 2008
  • Carboplatin vs Radiation in Testicular Cancer

    A single dose of carboplatin is as effective as adjuvant radiotherapy and more effective in preventing contralateral disease in men with stage 1 seminoma.
    Medscape Medical News, June 10, 2008
  • Probe of Erythropoiesis-Stimulating Agents

    The preliminary work suggests that erythropoietin might not only have an effect on red blood cells, it might have an effect on tumor blood vessels as well. It is a provocative hypothesis that is generating fervent debate.
    Medscape Medical News, June 10, 2008
  • Combination Targeted Therapies in Renal Cancer

    Combining novel targeted agents has yielded promising results in preliminary trials, although combination regimens can cause more toxicity and efficacy might not necessarily be better than sequential dosing.
    Medscape Medical News, June 9, 2008
  • Different Molecular Phenotypes in Breast Cancer

    Sites of relapse and metastases might have different molecular phenotypes than the primary tumor in breast cancer, which might affect treatment decisions.
    Medscape Medical News, June 9, 2008
  • Lapatinib in Metastatic Breast Cancer

    Studies have shown benefit from lapatinib monotherapy, and lapatinib in combination with trastuzumab, bevacizumab, and the investigational agent pazopanib.
    Medscape Medical News, June 5, 2008
  • Chemopreventive Role for Celecoxib

    High-dose celecoxib reduced levels of Ki-67, a key biomarker in lung cancer, among patients at high risk for the disease.
    Medscape Medical News, June 5, 2008
  • PET Scan in Early-Stage NSCLC

    Preoperative staging with PET/CT and cranial imaging was more precise in identifying patients with mediastinal and extrathoracic disease, preventing stage-inappropriate surgery in some patients.
    Medscape Medical News, June 3, 2008
  • Acupuncture Effective After Neck Dissection

    Acupuncture provided significant reductions in pain, dysfunction, and xerostomia after neck dissection in patients with head and neck cancer, and was more effective than conventional therapies.
    Medscape Medical News,June 3, 2008
  • Vaginal Brachytherapy vs External-Beam Therapy

    The efficacy of vaginal brachytherapy is comparable to that of eternal beam radiation in the prevention of disease recurrence in high-risk patients with endometrial cancer, but gastrointestinal toxicity is lower.
    Medscape Medical News, June 2, 2008
  • KRAS Predicts Benefit from Cetuximab

    Researchers have identified a new marker for selecting patients for targeted therapy.
    Medscape Medical News, June 2, 2008
  • AVADO Trial Confirms Bevacizumab Benefit

    A second trial has shown that adding bevacizumab to a taxane significantly improves progression-free survival in metastatic breast cancer.
    Medscape Medical News, June 2, 2008
  • Combination Cetuximab Chemotherapy in NSCLC

    Cetuximab combined with cisplatin/vinorelbine showed a small overall survival benefit in patients with advanced non-small-cell lung cancer over chemotherapy alone.
    Medscape Medical News, June 2, 2008
  • Everolimus and Survival in Metastatic RCC

    Everolimus, an investigational mTor inhibitor, improved survival in patients with metastatic renal cell carcinoma whose disease had progressed after treatment with sunitinib and/or sorafenib.
    Medscape Medical News, June 1, 2008
  • Oral Capecitabine vs Conventional Chemo

    In older women with early-stage breast cancer, single-agent oral capecitabine was inferior to 2 different conventional chemotherapy regimens.
    Medscape Medical News, June 1, 2008
  • Zoledronic Acid and Early Breast Cancer

    For the first time, a bisphosphonate has shown a substantial clinical benefit in early breast cancer, reducing both local and distant disease.
    Medscape Medical News, June 1, 2008
  • ASCO Opening Press Briefing

    Experts praise the recent progress made in cancer research and treatment but lament the decline in funding.
    Medscape Medical News, May 30, 2008
  • Childhood Cancer Survivors and Heart Disease

    Children who survive cancer are at risk for premature cardiovascular disease and should be closely monitored for their whole lives.
    Medscape Medical News, May 21, 2008
  • Vitamin D Deficiency and Breast Cancer Outcomes

    Women deficient in vitamin D when diagnosed with breast cancer had significantly worse outcomes than those with normal levels.
    Medscape Medical News, May 21, 2008
  • Ewing's Sarcoma: More Frequent Chemotherapy

    Chemotherapy administered every 2 weeks rather than every 3 weeks improved outcomes in Ewing's sarcoma, and should now be the standard of care.
    Medscape Medical News, May 21, 2008
  • Pemetrexed Delays Relapse in NSCLC

    Maintenance therapy with pemetrexed doubled the time to progression for patients with non-small-cell lung cancer.
    Medscape Medical News, May 21, 2008
  • Breast MRI and Mastectomy Rates Have Risen

    Mayo Clinic researchers reporting a rise in mastectomy rates at the same time as an increase in preoperative breast MRI speculate that the two are related.
    Medscape Medical News, May 21, 2008
  • Findings to Be Presented at ASCO 2008 Meeting

    For the first time, the American Society of Clinical Oncology has released several key research findings ahead of its annual meeting, being held later this month.
    Medscape Medical News, May 20, 2008

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Clinical Oncology. These materials and the related activity are not sanctioned by the American Society of Clinical Oncology or the commercial supporter of the conference and do not constitute an official part of that conference.